Actively Recruiting
Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-12-13
370
Participants Needed
3
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to: 1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer 2. Describe occult cancer characteristics and spontaneous course of occult cancer Methodology The investigators will include 370 stroke patients with elevated D-dimer (≥ 820 μg/L) at the time of stroke, suspicion of ESUS after initial workup and without known cancer. The investigators will perform a follow-up telephone interview at one year to assess the occurrence of a new cancer and characterize the course of the disease. Significance Determining the real incidence of occult cancer in high-risk patients will help support the implementation of screening trials in the future. Faster detection and treatment of occult cancers would significantly impact patient' outcomes by offering faster cancer treatment and optimal secondary stroke prevention.
CONDITIONS
Official Title
Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent by patient or next of kin
- Age 18 years or older
- Acute ischemic stroke with symptom onset within 48 hours before admission
- Stroke with persistent symptoms lasting 24 hours or more, or acute brain infarction confirmed by CT or MRI
- D-dimer level 820 cg/L or higher measured after symptoms start and within 24 hours of admission
- Embolic stroke of unknown source (ESUS) after initial work-up including imaging and cardiac tests
You will not qualify if you...
- Known active cancer at time of index stroke
- Intravenous thrombolysis given before D-dimer measurement (unless external lab value available)
- New diagnosis of central nervous system cancer
- Patient or next of kin unlikely to comply or be available for follow-up interview
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Dept. of Neurology, Centre Hospital Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
2
Dept. of Neurology, Universitätsspital Basel
Basel, Switzerland, 4031
Actively Recruiting
3
Dept, of Neurology, Inselspital, University of Bern
Bern, Switzerland, 3010
Actively Recruiting
Research Team
S
Simon Jung, MD
CONTACT
M
Morin Beyeler, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here